Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Estracyt Capsules.
| Pharmaceutical Form |
|---|
|
Capsule. White, hard, gelatin capsules with “ESTRACYT” and “K Ph 750” printed in black ink. |
Estramustine phosphate 140 mg as estramustine sodium phosphate.
For the full list of excipients, see section 6.1
| Active Ingredient | Description | |
|---|---|---|
| Estramustine |
Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. |
| List of Excipients |
|---|
|
Talcum |
Brown glass bottle containing 100 capsules.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
PL 00057/0973
Date of first authorisation: 25 May 2002
Date of latest renewal: 13 Nov 2008
| Drug | Countries | |
|---|---|---|
| ESTRACYT | Estonia, Spain, France, Japan, Netherlands, Singapore, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
